HCV NS5A protein — Drug Target

All drugs that target HCV NS5A protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

NS5A inhibitor

Phase 3 pipeline (1)

• Placebo matching BMS-790052 · Bristol-Myers Squibb · NS5A inhibitor · Virology/Hepatology
  BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication.